Prostatype Genomics
Prostatype Genomics is a Swedish medical technology company focused on molecular diagnostics for prostate cancer. Its core product is the Prostatype® Test System, a gene-expression test used to support treatment decisions after a prostate cancer diagnosis, with commercial activity in selected European markets and the United States.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueMolecular gene test used to assess prostate cancer risk and guide treatment decisions.
Commercial testing and related service revenue from running the Prostatype® workflow.
Customers
The company sells into healthcare settings that diagnose and treat prostate cancer, where clinicians need additional information beyond standard pathology. Buyers are typically hospitals, laboratories, and healthcare systems that use the test to support treatment selection and reduce overtreatment. In the U.S., reimbursement and payer acceptance are important because they influence adoption and test utilization.
Buy the test to support prostate cancer treatment decisions for diagnosed patients
Use or distribute the test workflow and related sample analysis services
Not direct buyers in all cases, but reimbursement determines uptake and volume
Use the result as decision support when selecting treatment intensity
Strategy
The company’s strategy centers on commercializing Prostatype® in priority markets and building clinical evidence to support adoption. It also emphasizes reimbursement access, especially in the U.S., while keeping strategic flexibility through partnerships or a potential company sale.
The U.S. is a large prostate cancer market and a major source of future adoption
Reimbursement is central to scaling test volume in the U.S. healthcare system
Published data supports physician confidence, payer coverage, and partner interest
Commercial partners can accelerate distribution and market access
Geography
Prostatype Genomics is headquartered in Stockholm, Sweden, and operates from the Swedish market while commercializing its product in selected European markets and the United States. The company’s geography matters because adoption depends on local regulatory clearance, reimbursement pathways, and clinical practice patterns, especially in the U.S. and Europe.
Risks
The business depends on successful commercialization of a single core product, so adoption, reimbursement, and competitive differentiation are critical. It also carries typical medtech risks around regulation, patent challenges, study outcomes, and impairment of capitalized development costs if future cash flows do not materialize as expected.
- Commercialization and adoption riskImpact: HighLikelihood: High
Revenue depends on physicians, labs, and payers adopting Prostatype® at scale
Exposure: Single core product
- Reimbursement riskImpact: HighLikelihood: High
Coverage decisions, especially Medicare, affect U.S. test utilization
Exposure: U.S. market
- Competition and patent challenge riskImpact: HighLikelihood: Medium
Other medtech companies may launch equivalent tests or challenge IP
Exposure: Europe and U.S.
- Regulatory and study riskImpact: HighLikelihood: Medium
Clinical evidence and approvals can be delayed or fail to meet expectations
Exposure: Product launch and market access
- Impairment risk on intangible assetsImpact: HighLikelihood: Medium
Capitalized development costs depend on future commercialization cash flows
Exposure: Balance sheet intangibles
Accounting
Judgemental itemsThe balance sheet includes significant intangibles tied to Prostatype® commercialization
Impact: If sales or cash flows disappoint, write-downs may accelerate
The company depends on external funding until positive operating cash flow
Impact: Affects liquidity disclosures and continuity assumptions
Swedish K3 governs recognition and measurement choices in the financial statements
Impact: Shapes treatment of development costs, liabilities, and equity
Similar listed companies
Publicly listed companies with a comparable business focus.
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
NeoGenomics, Inc
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
Sera Prognostics, Inc
SERA · Services-Medical Laboratories
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Castle Biosciences, Inc
CSTL · Services-Medical Laboratories
Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in…
Last updated: 24/09/2026